Head-to-head · Cost-Efficiency Index
Go Vida Plena vs Rewinding RX
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Go Vida Plena
Cost-first shoppers who want spanish-speaking patients wanting GLP-1 access with culturally-tailored, Spanish-first support.
Visit Go Vida PlenaRewinding RX
Shoppers who want a flat, no-dose-upcharge price and are comparing the standard-dose product specifically, not the cheaper microdose line.
Visit Rewinding RXThe verdict
Go Vida Plena and Rewinding RX tie on the Cost-Efficiency Index at 66/100, so neither wins outright on the numbers. For most shoppers we'd start with Go Vida Plena (ranked #147, a hair above #150) — Cost-first shoppers who want spanish-speaking patients wanting GLP-1 access with culturally-tailored, Spanish-first support. But Rewinding RX is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Go Vida Plena.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Go Vida Plena | Rewinding RX |
|---|---|---|
| Cost-Efficiency Index | 66/100 | 66/100 |
| Semaglutide / mo | $179/mo (annual plan, compounded) | $139/mo (microdose tier, compounded) |
| Tirzepatide / mo | $269/mo (annual plan, compounded) | $189/mo (microdose tier, compounded) |
| Semaglutide / yr (modeled) | $2,148 | $1,668 |
| Tirzepatide / yr (modeled) | $3,228 | $2,268 |
| Coverage | Coverage not published | All 50 states |
| Oral / sublingual | Yes | No |
| Brand-name access | Yes | Compounded only |
| Rank here | #147 | #150 |
Go Vida Plena
66/100Where the value is
- Genuinely bilingual, Spanish-first platform serving an underserved market segment
- Offers both injectable and oral GLP-1 formulations
- Explicit, plain-language disclosure that compounded drugs are not FDA-approved
The tradeoffs
- Lowest advertised prices ($179/$269) require an annual plan commitment, not simple month-to-month billing
- Per-day price framing ('~$6/day') is used on the homepage, a common technique to understate the real monthly cost
Rewinding RX
66/100Where the value is
- Flat pricing within each product regardless of dose
- Publishes the FDA compounded-medication disclaimer and states pharmacies are '503A'/'503B' FDA-regulated facilities
- Corporate entity is disclosed (Rewinding RX Ltd.)
The tradeoffs
- Four separate GLP-1 SKUs exist at four different prices under similar names
- No compounding pharmacy is individually named, only generic '503A'/'503B' language
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.